Identifying predictors of poor prognosis in heart failure with preserved ejection fraction

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows patients diagnosed with heart failure with preserved ejection fraction (HFpEF) who have undergone thorough clinical and instrumental evaluations from 2013 to 2020. The aim is to assess the prognostic significance of various hemodynamic parameters, clinical characteristics, and biological markers in predicting adverse outcomes in HFpEF patients. Participants will be monitored for at least three years to identify independent predictors of poor prognosis. The study focuses on understanding how different factors contribute to the severity and progression of HFpEF.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed and data informed consent;
2. New York Heart Association (NYHA) class II-III heart failure;
3. Left ventricular ejection fraction \> 50%;
4. Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.

Exclusion Criteria:

1. Evidence of myocardial ischemia during stress echocardiography;
2. Significant lesions of the main coronary arteries;
3. Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);
4. Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;
5. Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy);
6. Primary pulmonary artery hypertension;
7. Significant left-sided structural valve disease;
8. Anemia (Hb \< 100 g/L);
9. Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 (CKD-EPI);
10. Non-cardiac conditions that complicate/exclude participation in the study;
11. Exacerbation of heart failure less than 3 months prior to study entry.

Where it's running

• Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADEMICIAN E.I.CHAZOV. of the Ministry of Health of the Russian Federation
  Moscow, Russia Recruiting

Study contacts

• Study coordinator: Artem G Ovchinnikov, MD, PhD, DSc
• Email: artcardio@mail.ru
• Phone: +74954146612

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Raising pacemaker heart rate during light exercise to lower left-heart pressures in HFpEF

  This test will try whether temporarily increasing the heart rate by adjusting pacemaker settings during light exercise can lower left-heart filling pressures and improve cardiac output in people with HFpEF who already have a DDD pacemaker.

  Recruiting at 2 sites Universitaire Ziekenhuizen KU Leuven · Hasselt and 1 other locations · NCT07270536

• Adding macitentan to dapagliflozin for people with HFmrEF/HFpEF and combined pre- and post-capillary pulmonary hypertension

  This test will see if adding macitentan to dapagliflozin helps adults with HFmrEF or HFpEF who also have combined pre- and post-capillary pulmonary hypertension.

  Recruiting at 9 sites Phase 4 Gachon University Gil Medical Center · Busan and 14 other locations · NCT07147114

• Triple-drug therapy (ARNI + SGLT2 inhibitor + MRA) for advanced HFpEF

  This study will test whether giving an ARNI together with an SGLT2 inhibitor and an MRA helps people with advanced HFpEF stay healthier over 52 weeks compared with individualized medical therapy.

  Recruiting Phase 2 National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Moscow · NCT06655480

• Understanding muscle blood flow in heart failure patients

  This study is testing how exercise training can improve blood flow to muscles and help Veterans with heart failure feel better and exercise more easily.

  Recruiting VA Office of Research and Development · Salt Lake City, Utah · NCT05115890

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.